Skip to main
PMN

PMN Stock Forecast & Price Target

PMN Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProMIS Neurosciences Inc. is positioned favorably within the biotechnology sector due to its advanced Alzheimer’s therapy candidate, PMN310, which has demonstrated a strong safety profile with a low incidence of amyloid-related imaging abnormalities (ARIA), potentially surpassing existing anti-amyloid treatments. The company’s Phase Ib PRECISE-AD study is over 85% enrolled, indicating robust ongoing clinical progress, with 6-month data expected in the second quarter of 2026, signaling a timely path to significant clinical milestones. Moreover, the burgeoning Alzheimer’s market presents a substantial commercial opportunity, enhancing the potential for ProMIS to capitalize on its innovative therapeutic approaches targeting neurodegenerative diseases.

Bears say

ProMIS Neurosciences Inc reported a net loss of $11.6 million for the third quarter of 2025, translating to a loss of $0.24 per share, indicating significant ongoing financial challenges that may hinder growth potential. The company faces critical risks, including the inability to demonstrate safety and efficacy of its lead candidate PMN310 compared to existing anti-amyloid therapies, which could jeopardize regulatory approvals in a competitive market. Additionally, the need for future financing raises concerns about possible dilution for existing shareholders, compounding the company's negative outlook amidst the increasing prevalence of Alzheimer's disease and associated market potential.

PMN has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProMIS Neurosciences Inc (PMN) Forecast

Analysts have given PMN a Strong Buy based on their latest research and market trends.

According to 3 analysts, PMN has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProMIS Neurosciences Inc (PMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.